Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Constitutional Mosaic Epimutations - a hidden cause of cancer?

Lønning PE, Eikesdal HP, Løes IM, Knappskog S.

Cell Stress. 2019 Mar 22;3(4):118-135. doi: 10.15698/cst2019.04.183. Review.

2.

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC.

Røsland GV, Dyrstad SE, Tusubira D, Helwa R, Tan TZ, Lotsberg ML, Pettersen IKN, Berg A, Kindt C, Hoel F, Jacobsen K, Arason AJ, Engelsen AST, Ditzel HJ, Lønning PE, Krakstad C, Thiery JP, Lorens JB, Knappskog S, Tronstad KJ.

Cancer Metab. 2019 Jun 1;7:6. doi: 10.1186/s40170-019-0197-8. eCollection 2019.

3.

Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers.

Bischof K, Knappskog S, Hjelle SM, Stefansson I, Woie K, Salvesen HB, Gjertsen BT, Bjorge L.

Sci Rep. 2019 Mar 27;9(1):5244. doi: 10.1038/s41598-019-41706-z.

4.

The circular RNome of primary breast cancer.

Smid M, Wilting SM, Uhr K, Rodríguez-González FG, de Weerd V, Prager-Van der Smissen WJC, van der Vlugt-Daane M, van Galen A, Nik-Zainal S, Butler A, Martin S, Davies HR, Staaf J, van de Vijver MJ, Richardson AL, MacGrogan G, Salgado R, van den Eynden GGGM, Purdie CA, Thompson AM, Caldas C, Span PN, Sweep FCGJ, Simpson PT, Lakhani SR, Van Laere S, Desmedt C, Paradiso A, Eyfjord J, Broeks A, Vincent-Salomon A, Futreal AP, Knappskog S, King T, Viari A, Børresen-Dale AL, Stunnenberg HG, Stratton M, Foekens JA, Sieuwerts AM, Martens JWM.

Genome Res. 2019 Mar;29(3):356-366. doi: 10.1101/gr.238121.118. Epub 2019 Jan 28.

PMID:
30692147
5.

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, Van't Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2019 Feb;566(7742):E1. doi: 10.1038/s41586-019-0883-2.

PMID:
30659290
6.

Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.

Choi MH, Mejlænder-Andersen E, Manueldas S, El Jellas K, Steine SJ, Tjensvoll K, Sætran HA, Knappskog S, Hoem D, Nordgård O, Hovland R, Molven A.

BMC Cancer. 2019 Jan 5;19(1):11. doi: 10.1186/s12885-018-5195-7.

7.

Introducing nano-scale quantitative polymerase chain reaction.

Dyrstad SE, Tusubira D, Knappskog S, Tronstad KJ, Røsland GV.

Biochem Biophys Res Commun. 2018 Dec 2;506(4):923-926. doi: 10.1016/j.bbrc.2018.10.111. Epub 2018 Nov 2.

8.

BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only?

Lønning PE, Knappskog S.

Clin Epigenetics. 2018 Oct 22;10(1):128. doi: 10.1186/s13148-018-0566-0.

9.

Patterns of genomic evolution in advanced melanoma.

Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E, Myklebost O, Knappskog S, Lønning PE.

Nat Commun. 2018 Jul 10;9(1):2665. doi: 10.1038/s41467-018-05063-1.

10.

High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma.

Bischof K, Knappskog S, Stefansson I, McCormack EM, Trovik J, Werner HMJ, Woie K, Gjertsen BT, Bjorge L.

BMC Cancer. 2018 Jun 25;18(1):684. doi: 10.1186/s12885-018-4591-3.

11.

White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk.

Lønning PE, Berge EO, Bjørnslett M, Minsaas L, Chrisanthar R, Høberg-Vetti H, Dulary C, Busato F, Bjørneklett S, Eriksen C, Kopperud R, Axcrona U, Davidson B, Bjørge L, Evans G, Howell A, Salvesen HB, Janszky I, Hveem K, Romundstad PR, Vatten LJ, Tost J, Dørum A, Knappskog S.

Ann Intern Med. 2018 Mar 6;168(5):326-334. doi: 10.7326/M17-0101. Epub 2018 Jan 16.

PMID:
29335712
12.

APOBEC3A/B deletion polymorphism and cancer risk.

Gansmo LB, Romundstad P, Hveem K, Vatten L, Nik-Zainal S, Lønning PE, Knappskog S.

Carcinogenesis. 2018 Feb 9;39(2):118-124. doi: 10.1093/carcin/bgx131.

13.

The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells.

Huun J, Gansmo LB, Mannsåker B, Iversen GT, Sommerfelt-Pettersen J, Øvrebø JI, Lønning PE, Knappskog S.

Transl Oncol. 2017 Oct;10(5):806-817. doi: 10.1016/j.tranon.2017.07.006. Epub 2017 Aug 29.

14.

Genomic Evolution of Breast Cancer Metastasis and Relapse.

Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, Martincorena I, Alexandrov LB, Van Loo P, Haugland HK, Lilleng PK, Gundem G, Gerstung M, Pappaemmanuil E, Gazinska P, Bhosle SG, Jones D, Raine K, Mudie L, Latimer C, Sawyer E, Desmedt C, Sotiriou C, Stratton MR, Sieuwerts AM, Lynch AG, Martens JW, Richardson AL, Tutt A, Lønning PE, Campbell PJ.

Cancer Cell. 2017 Aug 14;32(2):169-184.e7. doi: 10.1016/j.ccell.2017.07.005.

15.

Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines.

Huun J, Lønning PE, Knappskog S.

Cell Death Discov. 2017 May 22;3:17026. doi: 10.1038/cddiscovery.2017.26. eCollection 2017.

16.

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.

Yndestad S, Austreid E, Svanberg IR, Knappskog S, Lønning PE, Eikesdal HP.

Oncotarget. 2017 Jun 20;8(25):41227-41241. doi: 10.18632/oncotarget.17167.

17.

Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells.

Huun J, Gansmo LB, Mannsåker B, Iversen GT, Øvrebø JI, Lønning PE, Knappskog S.

BMC Cell Biol. 2017 Apr 17;18(1):17. doi: 10.1186/s12860-017-0134-z.

18.

Somatic mutations reveal asymmetric cellular dynamics in the early human embryo.

Ju YS, Martincorena I, Gerstung M, Petljak M, Alexandrov LB, Rahbari R, Wedge DC, Davies HR, Ramakrishna M, Fullam A, Martin S, Alder C, Patel N, Gamble S, O'Meara S, Giri DD, Sauer T, Pinder SE, Purdie CA, Borg Å, Stunnenberg H, van de Vijver M, Tan BK, Caldas C, Tutt A, Ueno NT, van 't Veer LJ, Martens JW, Sotiriou C, Knappskog S, Span PN, Lakhani SR, Eyfjörd JE, Børresen-Dale AL, Richardson A, Thompson AM, Viari A, Hurles ME, Nik-Zainal S, Campbell PJ, Stratton MR.

Nature. 2017 Mar 30;543(7647):714-718. doi: 10.1038/nature21703. Epub 2017 Mar 22.

19.

Tumor cells interact with red blood cells via galectin-4 - a short report.

Helwa R, Heller A, Knappskog S, Bauer AS.

Cell Oncol (Dordr). 2017 Aug;40(4):401-409. doi: 10.1007/s13402-017-0317-9. Epub 2017 Mar 14.

PMID:
28293788
20.

High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function.

Yndestad S, Austreid E, Knappskog S, Chrisanthar R, Lilleng PK, Lønning PE, Eikesdal HP.

Breast Cancer Res Treat. 2017 May;163(1):177-190. doi: 10.1007/s10549-017-4160-5. Epub 2017 Feb 17.

21.

MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.

Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S.

BMC Cancer. 2017 Feb 3;17(1):97. doi: 10.1186/s12885-017-3094-y.

22.

Prevalence of the CHEK2 R95* germline mutation.

Knappskog S, Leirvaag B, Gansmo LB, Romundstad P, Hveem K, Vatten L, Lønning PE.

Hered Cancer Clin Pract. 2016 Sep 27;14:19. eCollection 2016.

23.

Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.

Smid M, Rodríguez-González FG, Sieuwerts AM, Salgado R, Prager-Van der Smissen WJ, Vlugt-Daane MV, van Galen A, Nik-Zainal S, Staaf J, Brinkman AB, van de Vijver MJ, Richardson AL, Fatima A, Berentsen K, Butler A, Martin S, Davies HR, Debets R, Gelder ME, van Deurzen CH, MacGrogan G, Van den Eynden GG, Purdie C, Thompson AM, Caldas C, Span PN, Simpson PT, Lakhani SR, Van Laere S, Desmedt C, Ringnér M, Tommasi S, Eyford J, Broeks A, Vincent-Salomon A, Futreal PA, Knappskog S, King T, Thomas G, Viari A, Langerød A, Børresen-Dale AL, Birney E, Stunnenberg HG, Stratton M, Foekens JA, Martens JW.

Nat Commun. 2016 Sep 26;7:12910. doi: 10.1038/ncomms12910.

24.

MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer.

Helwa R, Gansmo LB, Romundstad P, Hveem K, Vatten L, Ryan BM, Harris CC, Lønning PE, Knappskog S.

Sci Rep. 2016 Sep 14;6:33153. doi: 10.1038/srep33153.

25.

Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection.

Sveen A, Løes IM, Alagaratnam S, Nilsen G, Høland M, Lingjærde OC, Sorbye H, Berg KC, Horn A, Angelsen JH, Knappskog S, Lønning PE, Lothe RA.

PLoS Genet. 2016 Jul 29;12(7):e1006225. doi: 10.1371/journal.pgen.1006225. eCollection 2016 Jul.

26.

Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.

Flågeng MH, Larionov A, Geisler J, Knappskog S, Prestvik WS, Bjørkøy G, Lilleng PK, Dixon JM, Miller WR, Lønning PE, Mellgren G.

J Steroid Biochem Mol Biol. 2017 Jan;165(Pt B):228-235. doi: 10.1016/j.jsbmb.2016.06.011. Epub 2016 Jun 22.

PMID:
27343990
27.

EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.

Eskilsson E, Rosland GV, Talasila KM, Knappskog S, Keunen O, Sottoriva A, Foerster S, Solecki G, Taxt T, Jirik R, Fritah S, Harter PN, Välk K, Al Hossain J, Joseph JV, Jahedi R, Saed HS, Piccirillo SG, Spiteri I, Leiss L, Euskirchen P, Graziani G, Daubon T, Lund-Johansen M, Enger PØ, Winkler F, Ritter CA, Niclou SP, Watts C, Bjerkvig R, Miletic H.

Neuro Oncol. 2016 Dec;18(12):1644-1655. Epub 2016 Jun 10. Erratum in: Neuro Oncol. 2016 Dec;18(12 ):e2.

28.

Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M; ICGC Prostate Cancer Working Group; ICGC Bone Cancer Working Group; ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, Van't Veer LJ, Tan BK, Aparicio S, Span PN, Martens JW, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Myklebost O, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Bova GS, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PJ, Stratton MR.

Genome Res. 2016 May;26(5):717.2. doi: 10.1101/gr.206557.116. No abstract available.

29.

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2016 Jun 2;534(7605):47-54. doi: 10.1038/nature17676. Epub 2016 May 2. Erratum in: Nature. 2019 Feb;566(7742):E1.

30.

Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate.

Gansmo LB, Vatten L, Romundstad P, Hveem K, Ryan BM, Harris CC, Knappskog S, Lønning PE.

Oncotarget. 2016 May 10;7(19):28637-46. doi: 10.18632/oncotarget.8705.

31.

Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.

Løes IM, Immervoll H, Sorbye H, Angelsen JH, Horn A, Knappskog S, Lønning PE.

Int J Cancer. 2016 Aug 1;139(3):647-56. doi: 10.1002/ijc.30089. Epub 2016 Apr 4.

32.

The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer.

Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Dørum A, Birkeland E, Hveem K, Romundstad P, Vatten L, Lønning PE, Knappskog S.

Tumour Biol. 2016 Aug;37(8):10697-702. doi: 10.1007/s13277-016-4940-2. Epub 2016 Feb 11.

33.

Promoter SNPs rs116896264 and rs73933062 form a distinct haplotype and are associated with galectin-4 overexpression in colorectal cancer.

Helwa R, Ramadan M, Abdel-Wahab AH, Knappskog S, Bauer AS.

Mutagenesis. 2016 Jul;31(4):401-8. doi: 10.1093/mutage/gev086. Epub 2015 Dec 16.

PMID:
26681582
34.

MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung-, and prostate cancer risk.

Gansmo LB, Romundstad P, Birkeland E, Hveem K, Vatten L, Knappskog S, Lønning PE.

Cancer Med. 2015 Dec;4(12):1901-7. doi: 10.1002/cam4.555. Epub 2015 Oct 16.

35.

Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer.

Flågeng MH, Knappskog S, Gjerde J, Lønning PE, Mellgren G.

PLoS One. 2015 Aug 6;10(8):e0134351. doi: 10.1371/journal.pone.0134351. eCollection 2015.

36.

Subclonal diversification of primary breast cancer revealed by multiregion sequencing.

Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, Aas T, Alexandrov LB, Larsimont D, Davies H, Li Y, Ju YS, Ramakrishna M, Haugland HK, Lilleng PK, Nik-Zainal S, McLaren S, Butler A, Martin S, Glodzik D, Menzies A, Raine K, Hinton J, Jones D, Mudie LJ, Jiang B, Vincent D, Greene-Colozzi A, Adnet PY, Fatima A, Maetens M, Ignatiadis M, Stratton MR, Sotiriou C, Richardson AL, Lønning PE, Wedge DC, Campbell PJ.

Nat Med. 2015 Jul;21(7):751-9. doi: 10.1038/nm.3886. Epub 2015 Jun 22.

37.

Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.

Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE.

Mol Oncol. 2015 Oct;9(8):1553-64. doi: 10.1016/j.molonc.2015.04.008. Epub 2015 May 8.

38.

Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M; ICGC Prostate Cancer Working Group; ICGC Bone Cancer Working Group; ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, van't Veer LJ, Tan BK, Aparicio S, Span PN, Martens JW, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Myklebost O, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Bova SG, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PJ, Stratton MR.

Genome Res. 2015 Jun;25(6):814-24. doi: 10.1101/gr.190470.115. Epub 2015 May 11. Erratum in: Genome Res. 2016 May;26(5):717.2.

39.

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.

Gansmo LB, Knappskog S, Romundstad P, Hveem K, Vatten L, Lønning PE.

Int J Cancer. 2015 Jul 1;137(1):96-103. doi: 10.1002/ijc.29358. Epub 2014 Dec 10.

40.

Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649).

Knappskog S, Gansmo LB, Dibirova K, Metspalu A, Cybulski C, Peterlongo P, Aaltonen L, Vatten L, Romundstad P, Hveem K, Devilee P, Evans GD, Lin D, Van Camp G, Manolopoulos VG, Osorio A, Milani L, Ozcelik T, Zalloua P, Mouzaya F, Bliznetz E, Balanovska E, Pocheshkova E, Kučinskas V, Atramentova L, Nymadawa P, Titov K, Lavryashina M, Yusupov Y, Bogdanova N, Koshel S, Zamora J, Wedge DC, Charlesworth D, Dörk T, Balanovsky O, Lønning PE.

Oncotarget. 2014 Sep 30;5(18):8223-34.

41.

Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens.

Løes IM, Immervoll H, Angelsen JH, Horn A, Geisler J, Busch C, Lønning PE, Knappskog S.

Tumour Biol. 2015 Feb;36(2):1003-13. doi: 10.1007/s13277-014-2711-5. Epub 2014 Oct 16.

42.

Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.

Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Fullam A, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP, Nik-Zainal S, Alexandrov L, Behjati S, Yates LR, Bolli N, Mudie L, Hardy C, Martin S, McLaren S, O'Meara S, Anderson E, Maddison M, Gamble S, Foster C, Warren AY, Whitaker H, Brewer D, Eeles R, Cooper C, Neal D, Lynch AG, Visakorpi T, Isaacs WB, Veer LV, Caldas C, Desmedt C, Sotiriou C, Aparicio S, Foekens JA, Eyfjörd JE, Lakhani SR, Thomas G, Myklebost O, Span PN, Børresen-Dale AL, Richardson AL, Van de Vijver M, Vincent-Salomon A, Van den Eynden GG, Flanagan AM, Futreal PA, Janes SM, Bova GS, Stratton MR, McDermott U, Campbell PJ; ICGC Breast Cancer Group; ICGC Bone Cancer Group; ICGC Prostate Cancer Group.

Science. 2014 Aug 1;345(6196):1251343. doi: 10.1126/science.1251343.

43.

MDM2 SNP309 and risk of endometrial cancer.

Knappskog S, Lønning PE.

Tumour Biol. 2014 Aug;35(8):7285-6. doi: 10.1007/s13277-014-2244-y. Epub 2014 Jun 26. No abstract available.

PMID:
24964960
44.

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy.

Eikesdal HP, Knappskog S, Aas T, Lønning PE.

Acta Oncol. 2014 Oct;53(10):1347-55. doi: 10.3109/0284186X.2014.922215. Epub 2014 Jun 9.

45.

MDM2 SNP309 and risk of cervical cancer.

Knappskog S, Lønning PE.

Tumour Biol. 2014 Jul;35(7):6185-6. doi: 10.1007/s13277-014-1910-4. Epub 2014 Apr 17. No abstract available.

PMID:
24740562
46.

Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.

Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N, Davies HR, Knappskog S, Martin S, Papaemmanuil E, Ramakrishna M, Shlien A, Simonic I, Xue Y, Tyler-Smith C, Campbell PJ, Stratton MR.

Nat Genet. 2014 May;46(5):487-91. doi: 10.1038/ng.2955. Epub 2014 Apr 13.

47.

Effects of SNP variants in the 17β-HSD2 and 17β-HSD7 genes and 17β-HSD7 copy number on gene transcript and estradiol levels in breast cancer tissue.

Straume AH, Knappskog S, Lønning PE.

J Steroid Biochem Mol Biol. 2014 Sep;143:192-8. doi: 10.1016/j.jsbmb.2014.02.003. Epub 2014 Feb 18.

48.

Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.

Flågeng MH, Knappskog S, Haynes BP, Lønning PE, Mellgren G.

PLoS One. 2013 Aug 22;8(8):e74618. doi: 10.1371/journal.pone.0074618. eCollection 2013.

49.

CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.

Astori A, Fredly H, Aloysius TA, Bullinger L, Mansat-De Mas V, de la Grange P, Delhommeau F, Hagen KM, Récher C, Dusanter-Fourt I, Knappskog S, Lillehaug JR, Pendino F, Bruserud Ø.

Oncotarget. 2013 Sep;4(9):1438-48.

50.

Signatures of mutational processes in human cancer.

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdés-Mas R, van Buuren MM, van 't Veer L, Vincent-Salomon A, Waddell N, Yates LR; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR.

Nature. 2013 Aug 22;500(7463):415-21. doi: 10.1038/nature12477. Epub 2013 Aug 14. Erratum in: Nature. 2013 Oct 10;502(7470):258. Imielinsk, Marcin [corrected to Imielinski, Marcin].

Supplemental Content

Loading ...
Support Center